Previous close | 2.8500 |
Open | 2.8500 |
Bid | 1.0000 |
Ask | 5.4000 |
Strike | 3.00 |
Expiry date | 2024-01-19 |
Day's range | 2.8500 - 2.8500 |
Contract range | N/A |
Volume | |
Open interest | 4 |
MOUNTAIN VIEW, Calif., October 05, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. T
RICHMOND, Va. & MOUNTAIN VIEW, Calif., September 08, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel
RICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) an